Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GenusGENSF 71 PEG Ratio is 1.08 as of Sep. 17, 2026, which is 69% below its 10-year median of 3.44. GuruFocus rates GENSF with a GF Score™ of 71/100 and a GF Value™ of $28.90. The stock has 4 warning signs investors should review. Among 105 Biotechnology companies, Genus ranks better than 61.9% on this metric.
PE Ratio without NRI / 5-Year EBITDA Growth Rate*
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Genus's PE Ratio without NRI is 21.41. Genus's 5-Year EBITDA growth rate is 19.80%. Therefore, Genus's PEG Ratio for today is 1.08.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Genus's PEG Ratio or its related term are showing as below:
GENSF'
s PEG Ratio Range Over the Past 10 Years
Min: 0.88 Med: 3.44 Max: 14.9
Current: 1.01
During the past 13 years, Genus's highest PEG Ratio was 14.90. The lowest was 0.88. And the median was 3.44.
GENSF's PEG Ratio is ranked better than 61.9% of 105
companies
in the Biotechnology industry
Industry Median: 1.65
vs GENSF: 1.01
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Genus PEG Ratio Related Terms
Genus PEG Ratio Historical Data
* Premium members only.
The historical data trend for Genus's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Genus's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genus PEG Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genus's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Genus's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Genus (GENSF) has a PEG Ratio of 1.08 as of Sep. 17, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Genus and its competitors. This is 69% below median its historical median of 3.44. Over the past decade, Genus' PEG Ratio has ranged from 0.88 to 14.90. According to the industry distribution chart, Genus ranks #40 out of 105 companies in the Biotechnology industry, placing it in the top 38.1%.
Is Genus' PEG Ratio too high?
Genus' current PEG Ratio of 1.08 is 69% below median its 10-year median of 3.44. Over the past 10 years, this metric has ranged from a low of 0.88 to a high of 14.90. The Biotechnology industry median PEG Ratio is 1.65. Genus' value of 1.08 is 34.5% below this industry median. Based on the distribution chart, Genus ranks #40 out of 105 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Genus has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Genus' PEG Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genus ranks #40 out of 105 companies for PEG Ratio. This puts Genus in the upper half of its industry. The industry median PEG Ratio is 1.65. Genus' value of 1.08 is 34.5% below this benchmark. Historically, Genus' own PEG Ratio has ranged from 0.88 to 14.90 over the past decade. While the company's 10-year median is 3.44 vs. the industry median of 1.65, Genus has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 1.65, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genus's current PEG Ratio of 1.08 is 34.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Genus and its competitors. For the Biotechnology industry, the median PEG Ratio is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genus's current PEG Ratio is 1.08, which is 69% below median its own 10-year median of 3.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genus stock overvalued right now?
Genus (GENSF) has a current PEG Ratio of 1.08. The stock's GF Value™ is $28.90, compared to a current price of $31.07 — trading 7.5% above its estimated fair value. The current PEG Ratio is 1.08, which is 69% below median its 10-year median of 3.44 and 34.5% below the Biotechnology industry median of 1.65. Genus' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Genus (GENSF), the current PEG Ratio is 1.08 as of Sep. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genus (GENSF) Overvalued in 2026?
Based on GuruFocus' analysis, Genus stock appears to be overvalued.
The current stock price of $31.07 is trading 7.5% above its estimated GF Value™ of $28.90.
Key valuation signals for GENSF:
PEG Ratio: 1.08 (69% below median its 10-year median of 3.44)
GF Value™: $28.90 vs. price of $31.07 (7.5% above fair value)
Industry Position: 34.5% below the Biotechnology median (#40 of 105)
No single metric tells the full story. See the GENSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genus PLC is an animal genetics company focused on improving cattle and pig populations to support sustainable food production. The company operates through two main business units: one providing bovine genetics mainly for dairy and beef cattle, and the other offering porcine genetics for pork production. Genus develops genetically superior breeding animals using scientific techniques. It generates revenue by selling genetics, including semen and embryos, as well as through related services under multi-year royalty agreements. The principal activities of each segment are: (a) Genus PIC porcine sales business, (b) Genus ABS: bovine sales business, and (c) Genus Research and Development: spending on research and development.
71GF Score
Get the complete analysis for GENSF
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GENSF has been successfully added to your 
